Unlike targeting with invariant chains, using neoantigens where T-cells were the only adaptive mediators of tumour resistance, it was observed that the effect of therapy was dependent on both CD4+ and CD8+ T-cells combined [116,117]. Here, CD8A is linked to neoplasm.